Top 10 Gene Editing Companies

Published: November 2025

Genome editing technologies hold a promise to expand the ability to explore and alter any genome, as well as constitute a new and promising paradigm to understand the underlying cause of the associated diseases. Moreover, in the last decade, the CRISPR / Cas9 system has created a significant impact on both conventional and applied biological research. However, careful considerations must be made while incorporating any gene editing tool for therapeutic intervention in order to ensure efficiency, precision, safety and targeted delivery in the cells.

Moreover, owing to the advancements in gene editing technologies, the reliability on the stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers (gene therapy and cell therapy developers) to address the challenges in effective delivery of gene editing tools and improve the clinical outcome of the therapeutics by achieving the desired genetic manipulation.

Roots Analysis has conducted an exhaustive study on Genome Editing Market featuring the current market landscape and future opportunity for the companies engaged in genome editing market, over a span of next 10 years.

Top Gene Editing Companies

Arcturus Therapeutics
ArsenalBio
Beam Therapeutics
Caribou Biosciences
Century Therapeutics
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Prime Medicine
Vor Biopharma

The figure below highlights the top gene editing companies:

Top 10 US Companies to watch Genome Editing Market

Interested in exploring all 135+ gene editing companies and their recent initiatives?

Discover Below the Details on Top Gene Editing Companies

Let us dive deep into the details of the top gene editing companies. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

1. Arcturus Therapeutics

Company Overview

Arcturus Therapeutics is a US-based company that specializes in the development of mRNA therapeutics through its LNP-based delivery platforms, LUNAR and STARR. The company claims to leverage these technologies for upregulation of a gene, gene editing and gene silencing. In addition, the company is also engaged in the development of mRNA vaccines for the treatment of various infectious diseases (such as coronavirus, seasonal and pandemic influenza).

Key Parameters	Specifications
Type of Gene Editing Technique	CRISPR-Cas system, TALENs, Meganucleases
Gene Editing Approach	Knock-in, Knock-out
Highest Phase of Drug Development Supported	Clinical
Application Area	Drug Discovery

Recent Developments

In 2025, company has participated in the 43rd Annual J.P. Morgan Healthcare Conference, held in San Francisco, US. In the recent past, company has participated in multiple conferences, namely Jefferies London Healthcare Conference, Canaccord Genuity 44th Annual Growth Conference and 47th Annual European Cystic Fibrosis Conference.

To know more about the offerings and recent initiatives of Arcturus Therapeutics in Genome Editing Market, access full report.

2. Arsenal Bio

Company Overview

Arsenal Bio is a US-based clinical-stage company focused on developing autologous integrated circuit T-cell (ICT) therapies and programmable cell therapies for patients with solid tumors. It is important to mention that Arsenal Biosciences utilizes a highly precise CRISPR-based technique known as CITE (CRISPR Integration of Transgene via Electroporation) in order to engineer synthetic biology modules into T-cells through a single genetic modification on Chromosome 11. The company aims to offer enhanced efficacy along with increased patient safety, using their programmable and computationally driven approach.

Key Parameters	Specifications
Type of Gene Editing Technique	CRISPR-Cas system
Gene Editing Approach	Knock-in
Application Area	Regenerative Medicine, Drug Discovery

Recent Developments taken up by Arsenal Bio in Genome Editing Market

In the recent past, Arsenal Bio participated in American Society of Gene and Cell Therapy (ASGCT) annual meeting. Moreover, it has secured capital investment worth USD 325 through a venture Series C funding round.

To know more about the offerings and recent initiatives of Arsenal Bio in genome editing market, access full report.

3. Beam Therapeutics

Company Overview

Beam Therapeutics is a US-based biotechnology company involved in the development of precision therapeutic products for critical disease indications using its proprietary next-generation CRISPR technologies, which are capable of making precise edits to single base pairs in DNA and RNA. These technologies are designed to offer various types of modifications, including gene activation, gene knock-out, gene correction, surface protein modification and multiplex gene editing. It is worth highlighting that the company owns a 100,000 square feet cGMP certified clinical / commercial facility in North Carolina.

Key Parameters	Beam's Base Editing Technology	Beam's CRISPR Cas12b Nuclease Technology
Type of Gene Editing Technique	CRISPR-Cas system (Base editing)	CRISPR-Cas system (Base editing)
Gene Editing Approach	Knock-in	Knock-in, Knock-out
Highest Phase of Drug Development Supported	Clinical	NA
Application Area	Regenerative Medicine, Drug Discovery	Regenerative Medicine, Drug Discovery

Recent Developments

In 2025, company received U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation to BEAM-101 for the treatment of sickle cell disease. In the same year, the company also participated in the American Society of Hematology (ASH) Annual Meeting, held in San Diego, US

To know more about the offerings and recent initiatives of Beam Therapeutics in genome editing market, access full report.

4. Caribou Biosciences

Company Overview

Caribou Biosciences is a clinical-stage biopharmaceutical company primarily engaged in the development of allogenic CAR-T and CAR-NK cell therapies for autoimmune diseases. Further, the company leverages its proprietary genome editing technology for the development of allogeneic cell therapies, along with its utilization for complex genome editing, including multiplex gene knockout and insertion. In addition to this, the company is advancing its product pipeline into clinical phases of development for various hematological malignancies.

Key Parameters	Specifications
Type of Gene Editing Technique	CRISPR-Cas system
Gene Editing Approach	Knock-in, Knock-out
Highest Phase of Drug Development Supported	Clinical
Application Area	Regenerative Medicine, Drug Discovery

Recent Developments taken up by Caribou Biosciences in Genome Editing Market

In 2025, company announced the positive Data from ANTLER phase 1 trial which is demonstrating efficacy and durability of Vispa-cel (CB-010). In addition, company appointed Tina Albertson as Chief Medical Officer and Terri Laufer to its scientific advisory Board.

To know more about the offerings and recent initiatives of Caribou Biosciences in genome editing market, access full report.

5. Century Therapeutics

Company Overview

Century Therapeutics is a biotechnology company dedicatedly working in the field of allogeneic cell therapies. The company’s diverse portfolio includes protein engineering and gene editing technologies aimed at developing induced pluripotent stem cell (iPSC)-derived therapies for both hematological and solid tumor cancers. Notably, Century Therapeutics leverages its proprietary Allo-Evasion technology to design cells having the ability to evade the immune host rejection. Additionally, the company employs CRISPR-MAD7-mediated homologous directed repair (HDR) to precisely knock-out and knock-in genes at specific sites within the iPSC genome. This method helps preserve genome integrity while achieving more consistent and predictable transgene expressions, offering advantages over viral-based or transposon-driven approaches.

Key Parameters	Specifications
Type of Gene Editing Technique	CRISPR-Cas system
Gene Editing Approach	Knock-out
Highest Phase of Drug Development Supported	Clinical
Application Area	Regenerative Medicine, Drug Discovery

Recent Developments

In November 2025, Century Therapeutics announced its first program CNTY-813, engineered iPSC-derived beta islets for type 1 diabetes.

To know more about the offerings and recent initiatives of Century Therapeutics in genome editing market, access full report.

6. CRISPR Therapeutics

Company Overview

CRISPR Therapeutics is a biopharmaceutical company focused on the development of transformative gene-based medicines, particularly for somatic (non-germline) diseases. The company is based in Boston, Massachusetts and operates through several centers located across the globe, such as Framingham, San Francisco and Switzerland. The company claims to be actively working on four focus areas, including gene-edited hematopoietic stem cells, immune-oncology, gene editing, and regenerative medicine. It is worth mentioning that the firm leverages its proprietary CRISPR / Cas9 gene editing platform for the development of gene therapy products.

Key Parameters	Specifications
Type of Gene Editing Technique	CRISPR-Cas system
Type of Gene Delivery Method	In vivo, Ex vivo
Highest Phase of Drug Development Supported	Clinical
Application Area	Plant Gene Editing, Regenerative Medicine, Drug Discovery

Recent Developments taken up by CRISPR Therapeutics in Genome Editing Market

In November 2025, CRISPR Therapeutics announced the positive results of Phase I trial of CTX310, an in vivo gene editing therapy that targets ANGPTL3.

To know more about the offerings and recent initiatives of CRISPR Therapeutics in genome editing market, access full report.

7. Editas Medicine

Company Overview

Editas Medicine is a biotechnology company which claims to have expertise in the field of genome editing. The company utilizes its Cas9 and Cas12a technologies for the development of next-generation genomic medicines (in vivo and ex vivo) for oncological and hematological disorders. In addition, the company is also working in the field of plant gene editing, regenerative medicine and drug discovery. It is worth highlighting that the company’s operational models are based on technology licensing and collaborative product development agreements with other stakeholders in the industry.

Key Parameters	Specifications
Type of Gene Editing Technique	CRISPR-Cas system
Gene Editing Approach	Knock-in
Highest Phase of Drug Development Supported	Clinical
Application Area	Plant Gene Editing, Regenerative Medicine, Drug Discovery

Recent Developments

In October 2025, the company presented the in vivo preclinical proof-of-concept data for EDIT-401, a one-time therapy, at 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress and the American Heart Association (AHA) Scientific Sessions 2025.

To know more about the offerings and recent initiatives of Editas Medicine in genome editing market, access full report.

8. Intellia Therapeutics

Company Overview

Intellia Therapeutics is engaged in the development of In vivo and Ex vivo CRISPR-based therapeutics for the treatment of various chronic diseases, including genetic, oncological, and immunological disorders. The company is advancing its candidates into clinical stages of development and has positioned itself as a leader in CRISPR technology, claiming to be the first to demonstrate successful systemic CRISPR delivery in the human body. Additionally, Intellia’s NTLA-2002, an investigational In vivo CRISPR genome editing therapy for Hereditary Angioedema, has been granted Orphan Drug Designation and Priority Medicines (PRIME) Designation by the European Union, highlighting its potential in addressing rare and severe conditions.

It is worth highlighting that Intellia’s co-founder, Jennifer Doudna, was awarded the Nobel Prize in Chemistry in 2020 for her pioneering work in developing the CRISPR/Cas9 genome editing technology, which has revolutionized the potential for precise and effective treatment of various challenging diseases.

Key Parameters	Specifications
Type of Gene Editing Technique	CRISPR-Cas system (Base editing)
Gene Editing Approach	Knock-in, Knock-out
Highest Phase of Drug Development Supported	Clinical (In vivo), Preclinical (Ex vivo)
Application Area	Regenerative Medicine, Diagnostics

Recent Developments

In November 2025, company presented positive follow up data from the ongoing phase I clinical studies of nexiguran ziclumeran (nex-z) in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy.

To know more about the offerings and recent initiatives of Intellia Therapeutics in genome editing market, access full report.

9. Prime Medicine

Company Overview

Prime Medicine is a biotechnology company focused on the emerging field of prime editing. The company’s pipeline includes 18 programs, that are currently under development targeting a range of conditions, including cystic fibrosis, Duchenne muscular dystrophy, Friedreich’s ataxia, Huntington’s disease, and Fragile X Syndrome. Notably, Prime Medicine operates across three manufacturing facilities in Cambridge and a chemistry facility in Watertown, which support its research and development efforts.

Key Parameters	Specifications
Type of Gene Editing Technique	CRISPR-Cas system (Prime Editing)
Gene Editing Approach	Knock-out (Prime Editing); Knock-in, Knock-out (PASSIGE)
Highest Phase of Drug Development Supported	Preclinical
Application Area	Regenerative Medicine, Drug Discovery

Recent Developments

In August 2025, the company announced closing of secondary offering of 43,700,000 shares of its common stock.

To know more about the offerings and recent initiatives of Prime Medicine in genome editing market, access full report.

10. Vor Biopharma

Company Overview

Vor Biopharma is a biotechnology company extensively engaged in the development of engineered treatment-resistant HSCs (eHSCs) with an aim to prevent graft failure / cytopenia in the patients post treating them with CAR-T cells or antibody drug conjugates (ADCs). The company’s pipeline consists of both allogeneic and autologous cell therapies for the targeted treatment of hematological malignancies, including acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasm.

Key Parameters	Specifications
Type of Gene Editing Technique	CRISPR-Cas system (Base Editing)
Type of Gene Delivery Method	In vivo
Highest Phase of Drug Development Supported	Clinical
Application Area	Regenerative Medicine, Drug Discovery

Recent Developments

In November 2025, the company announced the pricing of secondary offering of 10,000,000 shares of its common stock.

To know more about the offerings and recent initiatives of Vor Biopharma in genome editing market, access full report.

What About Other Gene Editing Companies Around the World?

The above article features the ten top gene editing companies active selected from a pool of over 135 companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources: